Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14490MR)

This product GTTS-WQ14490MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14490MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11183MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ7010MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ590MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ10349MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ5229MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ9483MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ12126MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ11555MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW